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ABSTRACT: 
Pulmonary surfactant protein-D (SP-D) is a soluble collagenous C-type lectin with important 
anti-microbial and anti-inflammatory properties.  Although it is subject to functionally relevant 
modification by common polymorphisms and unregulated inflammation, the functional status of 
SP-D in cystic fibrosis (CF) remains unclear.  Given the importance of infection and 
inflammation in CF lung pathology we have undertaken the first systematic analysis of SP-D 
lectin activity in this population. 
By ELISA, we found that airway lavage fluid SP-D expression was greater in CF compared to 
control patients but was reduced in CF patients with infection and correlated negatively with 
markers of neutrophilic inflammation.  In a functional assay, the percentage of SP-D capable of 
binding zymosan rarely exceeded 60% in CF or control patients and similarly restricted binding 
activity was observed towards maltose-agarose.  SP-D lectin activity also correlated negatively 
with infection and neutrophilic inflammation but there was little evidence of major proteolytic 
degradation among the non-bound material.  SP-D which failed to bind zymosan exhibited 
features of lower oligomeric form compared to bound material when tested by native gel 
electrophoresis.  Furthermore, when separated by gel chromatography, high and low oligomeric 
populations of SP-D were observed in CF lavage fluid but only high oligomeric forms exhibited 
substantial lectin activity towards yeast derived mannan.   
Our data demonstrate that oligomeric heterogeneity underlies functional diversity amongst SP-
D in health and disease and that dynamic regulation of oligomerisation is an important feature 
of SP-D biology.  
 
Keywords: Cystic Fibrosis, Innate Immunity, Lung, Surfactant Protein-D, Lectin, Inflammation 
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1. INTRODUCTION: 
Surfactant protein-D (SP-D) is a soluble multimeric collagenous C-type lectin.  Although initially 
and most widely described as a lung specific protein, SP-D is also expressed at a number of 
other mucosal sites [1].    In common with other collectins including mannose binding lectin 
(MBL) and surfactant protein-A (SP-A), SP-D recognises carbohydrate structures on a wide 
range of pathogens - including viruses, bacteria and fungal species - in a calcium dependent 
fashion [2].  The consequences of such recognition vary among the collectins and in the case of 
SP-D, pathogen agglutination, inhibition of replication and enhanced phagocytosis are primary 
outcomes.  Clearly important, but less well understood, is the ability of SP-D to regulate 
inflammatory activity.  This aspect of SP-D biology is most apparent in the knockout mouse 
which develops a spontaneous and progressive emphysematous inflammatory lung disease [3].   
SP-D expression has been examined in a number of lung diseases, including cystic fibrosis (CF).  
Exacerbations characterised by protracted and ineffective neutrophil dominated inflammatory 
responses to pulmonary infection are a primary cause of progressive lung damage in CF and for 
this reason there has been much interest in the pulmonary innate immune system in this 
population.  Although a number of studies have been undertaken, a clear consensus on the 
status of SP-D in CF has not emerged.  Earlier studies demonstrated a near absence of SP-D in CF 
lung secretions [4], but more recently µg/ml quantities have been detected in CF 
bronchoalveolar lavage fluid (BALF) [5].   Furthermore, reports of a complete absence [5], or 
significant reduction [4, 6] of SP-D expression in CF patients with infection contrast with others 
demonstrating relatively abundant immunoreactive SP-D in patients infected with Pseudomonas 
aeruginosa [7].  Whilst the amount of detectable SP-D in CF BALF correlates negatively with 
markers of neutrophil activity and SP-D is susceptible to neutrophil mediated inactivation in 
vitro [5-10], the functional status of endogenous SP-D in CF lung secretions has not been 
systematically addressed.  This is important as physiological concentrations of calcium are 
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known to protect SP-D from neutrophil mediated protease inactivation [6, 9-11] and in some 
studies little or none of the SP-D found in CF exhibits features of proteolytic degradation [7, 12].   
For this reason we wished to examine whether the widely reported inactivation of SP-D by 
neutrophils in vitro is reflected in the functional status of this molecule in CF lung secretions.  
Here we examine the expression of SP-D in airway secretions from two independent CF cohorts 
and control patients.   We also report the first systematic assessment of the SP-D lectin activity 
in CF using a novel zymosan binding assay. 
 
2. MATERIALS AND METHODS: 
2.1.  Patient recruitment and sample processing: 
Samples were included from two independently collected cohorts of CF patients and a cohort of 
control patients (see Table 1) as follows:  
Cohort A (25 samples) was recruited from the Children’s CF unit at the University Hospital of 
Wales as previously described [13].  Lavage was collected by flexible bronchoscopy in 10/25 
cases with the remainder collected by non-bronchoscopic lavage.  In all cases lavage was 
conducted for diagnostic reasons by instillation of 1ml/kg normal saline (up to a maximum of 
20ml) which was immediately suctioned back.  A portion of this lavage, representing the 
bronchial airway, was available for this study.  Processing and storage of lavage fluid at -80°C 
occurred within 45 minutes of collection as previously described [13].  Briefly, lavage fluid was 
centrifuged at 500g/5 min at 4°C, cell free lavage was aliquoted at 25µl and stored at -80°C for 
later analysis.  Among CF cohort A, clinically significant microbes were cultured from 10 
samples (Pseudomonas aeruginosa (n=5), Burkholderia cepacia (n=1), Stenotrophomonas 
maltophilia (n=2; of which n=1 coincident with P. aerugionosa),  Aspergillus fumigatus (n=1), 
Moraxella catarrhalis (n=1), Haemophillus influenzae (n=2; of which n=1 coincident with M. 
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catarrhalis)). 15 samples either yielded no culturable microbes or yielded microbes suggestive 
of normal microflora (Klebsiella pneumonia, alpha haemolytic streptococci) or microbes not 
considered to be of clinical significance in the absence of other symptoms (Candida, coliforms).   
Control lavage was collected by non-bronchoscopic lavage from nine non-CF subjects  who were 
undergoing tonsillectomy and/or adenoidectomy at the University Hospital of Wales. These 
patients were well at the time of surgery and were not in receipt of medication for respiratory 
symptoms as previously reported [13].  Samples were processed and stored as described for CF 
cohort A.  For this cohort and CF cohort A, ethical approval was obtained from the South East 
Wales Local Research Ethics Committee and written informed consent was obtained.   
Cohort B (19 samples) was recruited as previously described [11] from Southampton General 
Hospital from children undergoing fiberoptic bronchoscopy for diagnostic reasons.    For cohort 
B, 3 x 10ml portions of normal saline were instilled and aspirated in children younger than 3 
years of age.  This was increased to 3 x 20ml portions in children > 3 years of age.  This sampling 
represents bronchoalveolar lavage (BAL).  The study was approved by the Southampton and 
Wessex Local Research Ethics Committees and written informed consent was obtained from the 
parents.  BAL from cohort B was initially filtered through a 100µm nylon cell strainer (BD 
Biosciences) prior to centrifugation at 500g/10 minutes at 4°C.  Aspirated cell free BALF was 
immediately stored at -80°C.  For this study, 1ml aliquots from cohort B were available.  
Consequently, one freeze/thaw cycle was undertaken on these samples to prepare 25µl aliquots 
subsequently used throughout the study.  A single freeze thaw step was found to have no 
discernible impact on SP-D binding activity and recovery when determined for three lavage 
fluid samples (data not shown).  Limited clinical data and no microbiology data were available 
for cohort B and this cohort was primarily used to independently replicate observations made 
with the main cohort A.  Owing to some differences in collection and processing methodologies, 
no direct comparison was made between cohort B and either cohort A or the control cohort. 
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Immediately prior to analysis, samples from both cohorts were thawed on ice and subjected to 
micro-centrifugation at 10,000g for 1 minute.  Not all samples from the original studies were 
available for analysis here.   
2.2. Reagents: 
Unless otherwise stated, all reagents were from Fisher Scientific (Loughborough, UK).  Affinity 
purified goat anti-human SP-D raised against recombinant human SP-D was from R&D systems 
(Abingdon, UK).  Minimally cross reactive HRPO-conjugated donkey anti-goat IgG was from 
Jackson ImmunoResearch (Suffolk, UK).  Native SP-D was purified from pulmonary alveolar 
proteinosis bulk lavage as previously described [14], and stored at -80°C in the presence of 
1mM EDTA.  
2.3.  ELISA: 
SP-D was quantified in lavage fluid using a two monoclonal antibody sandwich ELISA from 
Hycult Biotech (Uden, Netherlands) according to the manufacturer’s instructions (measurable 
range: 6.3-400ng/ml).  Lavage samples were diluted between 1:2 and 1:100 and measured in 
duplicate.  Values for CXCL8 have previously been reported in cohort A [13] but not in the 
context of SP-D expression; this novel analysis is reported here. 
2.4.  Elastase activity assays: 
Values for elastase activity in cohorts A and B have been previously reported [11, 13] but not in 
the context of SP-D expression; this novel analysis is reported here. 
2.5.  Zymosan and maltose-agarose binding assays: 
10µl of a Zymosan-A suspension (1% w/v in 154mM NaCl) was added to a 0.5ml 
microcentrifuge tube and washed twice with 10 volumes of TBS-Ca (20mM Tris-HCl, 154mM 
NaCl, 20mM CaCl2; pH 7.6) with microcentrifugation at 10,000g (13,000rpm at r=5.3cm) for 1 
minute between washes.  The pellet was resuspended with 10µl of TBS-Ca and 10µl of either 
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freshly thawed BALF or, as a positive control, 10µl of native SP-D diluted to 2 or 20µg/ml in 
154mM NaCl with 1.5mg/ml protease free BSA (Sigma, Dorset, UK) to give a final concentration 
of 10mM CaCl2 in all binding assays.  Where Ca2+ or carbohydrate dependence of the binding 
assay was tested, native SP-D or lavage was diluted to give a final concentration of 10mM EDTA 
in TBS or 100mM D-Maltose plus 10mM CaCl2 in TBS in the binding assay.  In some cases, 1mM 
PMSF was included to inhibit serine protease activity in assays where EDTA was used.  Where 
the capacity of lavage to influence native SP-D binding to zymosan was tested, 10µl of native SP-
D (2µg/ml) in TBS-Ca was pre-incubated with 10µl of lavage prior to incubation with zymosan.   
For all assay formats, samples were incubated for 30 minutes at 37°C with occasional gentle 
mixing to maintain zymosan in suspension over the course of the assay.  Post assay, samples 
were microcentrifuged at 10,000g for 1 minute and the supernatant was carefully aspirated to a 
fresh tube, avoiding disturbance of the zymosan pellet.  Following aspiration of the supernatant, 
the zymosan pellet was washed once with 100µl TBS-Ca as described above and the washed 
pellet was resuspended in 20µl TBS with 20mM EDTA.  Where samples were subsequently 
subjected to SDS-PAGE both pellet and supernatant fractions were immediately treated with 
SDS sample buffer with β-mercaptoethanol as a reducing agent and boiled at 100°C for 2 
minutes prior to electrophoretic separation. For native-PAGE, samples were treated with cold 
sample buffer without SDS but supplemented with 0.002% Coomassie Blue G250 (Sigma, UK).  
Samples were not boiled but immediately separated as described below.  The reproducibility of 
the zymosan binding assay was confirmed by assaying at least seven lavage samples from this 
and a previous study [15] at different time points up to 10 months apart (data not shown). 
Maltose-agarose pull down assays were similar to the zymosan binding assays with the 
following differences.  10µl of maltose agarose (Sigma, Dorset, UK) was washed three times in 
1ml TBS-Ca prior to commencement of the binding assay.  Binding steps for both parallel 
zymosan and maltose-agarose assays were carried out on a flat bed roller to avoid settling of the 
maltose-agarose during the assay.  Assays were carried out in a final volume of 30µl, with only 
20µl of the supernatant fraction aspirated for SDS-PAGE to avoid disturbing the agarose pellet; 
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once washed, the pellet was resuspended in 30µl of TBS-EDTA, 20µl of which was prepared for 
for SDS-PAGE as described above. 
2.6.  Native- and SDS-PAGE, Western Blot and densitometry: 
Native PAGE was performed using NuPage 3-8% Tris-Acetate gels (Life Technologies, UK) and a 
tris-glycine buffer system where the cathode buffer was supplemented with 0.002% Coomassie 
Blue G250. Electrophoresis proceeded for 90-120 min at a constant voltage of 150V.  Proteins 
were transferred to nitrocellulose using NuPage Transfer buffer (Life Technologies, UK) 
supplemented with 10% methanol at a constant voltage of 100V for 1 hour.  For proteins 
separated under denatured and reduced conditions SDS-PAGE was performed using 10% gels 
with a 4% stacking gel.  Gels were separated at a constant current of 45mA per gel for 45-
60min.  Proteins were transferred to nitrocellulose in a tris-glycine buffer supplemented with 
20% methanol at a constant voltage of 100V for 1 hour.  In all cases, following transfer to 
nitrocellulose, blots were blocked for 30 min at room temperature with PBS 5% w/v skimmed 
milk powder (PBS-milk).  Blots were incubated overnight at 4°C with 0.1µg/ml goat anti-human 
SP-D in PBS-milk.  Blots were washed three times with PBS-0.05% v/v Tween and once with 
PBS.  Blots were incubated with minimally cross-reactive HRPO-conjugated donkey anti-goat 
IgG for 45 min at room temperature, washed three times with PBS-Tween, three times with PBS 
and developed using ECL prime substrate (GE Lifesciences, UK) prior to exposure to X-Ray film 
(Fuji, UK). The limit of sensitivity of SP-D detection by western blot was approximately 5ng/lane 
(equivalent to 500ng/ml under the conditions used here) and lavage samples with ELISA 
determined SP-D below this level were not detectable by western blot in this study. 
Developed blots were scanned and the entire blot area was uniformly adjusted for brightness 
and contrast.  Presented images represent all bands visible in lanes from the original blot.  
Densitometry was performed on the blots using ImageJ v1.42 as previously described [13] and 
percentage zymosan bound SP-D for any given data point refers to the percentage of the total 
band area present in the pellet fraction.  As SP-D exists in a number of oligomeric forms of 
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differing molecular weights, densitometry was only undertaken on samples reduced with β-
mercaptoethanol immediately prior to SDS-PAGE.  Reducing all SP-D oligomeric forms to single 
subunits ensured equivalent transfer efficiency and antibody reactivity of bands in pellet and 
supernatant fractions during western blot which is essential for accurate comparison of SP-D 
content in each fraction. 
2.7.  Analytical gel filtration and mannan binding assays: 
Lavage fluid (200µl) from six CF patients was applied to a Superose 6 10/300GL (GE 
Lifesciences, UK) column and was eluted in TBS-1mM EDTA at a flow rate of 24ml/h on an 
AKTAprime (GE Lifesciences, UK), collecting 0.8ml fractions which were immediately 
transferred to ice.  Fractions were assayed for SP-D by a sandwich ELISA as described (Leth-
Larsen 2003), except the capture antibody was replaced with a polyclonal rabbit antibody 
raised against a recombinant fragment of human SP-D, as previously reported [16].  Plates were 
developed with 3,3’,5,5’-Tetramethylbenzidine (TMB) (Sigma, UK) and arrested with H2SO4 
before absorbance was measured at 450nm on a SpectraMax 340PC spectrophotometer 
(Molecular Devices, UK). 
Fractions were also assayed for specific SP-D lectin activity in a solid phase mannan binding 
assay as follows:  Maxisorp 96-well plates (Nunc, Denmark) were coated overnight at 37°C with 
50µg/ml mannan from  S. cerevisiae (Sigma, UK) and blocked with TBS 0.05% Tween 20 (TBST).  
Gel chromatography fractions were made 0.05% (v/v) with respect to Tween 20 and 10mM 
with respect to either CaCl2 or EDTA.  Fractions were applied to mannan coated plates for 90 
minutes at room temperature.  Plates were washed three times with TBST-10mM calcium 
(TBST-C) or TBST-10mM EDTA (TBST-E) and goat anti-SP-D (1µg/ml) was applied in TBST-C 
for 60 minutes at room temperature.  Plates were washed and HRPO-conjugated minimally 
cross reactive donkey anti-goat IgG was applied for 30 minutes at room temperature.  Plates 
were washed, developed with TMB and arrested with H2SO4 before absorbance was measured 
at 450nm on a SpectraMax 340PC  spectrophotometer (Molecular Devices, UK). 
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2.8. Statistics 
Unless otherwise indicated, all data presented in the text refer to (median; interquartile range).  
Two group comparisons of non-parametric data were undertaken using the Mann-Whitney test.   
Spearman’s r-values are used to describe correlations.  In all cases statistical significance was 
achieved at p<0.05.  Data remained statistically significant after the application of Holm’s 
sequential Bonferroni correction where appropriate [17].  All data were analysed using 
GraphPad Prism v5.01 (GraphPad Software Inc). 
3. RESULTS: 
Table 1:  Description of cohorts under study. 
Data are expressed as median (range) or as number of samples (N). aNK=not known.  bLung 
function data were available for a proportion of cohort A and B and were not available for 
children <4 years of age.  cPlease see materials and methods for additional information.  
dDifferential cell counts were available for a proportion of the cohort as previously described 
[13].  eElastase activity values refer to elastase positive samples only. 
 Control CF Cohort A CF Cohort B 
N 9 25 19 
Age (decimal years) 8.28 (6.53-10.93) 6.41 (0.07-15.74) 9.67 (0.39-17.92) 
Sex (M:F) 5:4 15:10 NKa 
Weight (kg) NK 22 (4.8-81.2) NK 
BMISDS NK 0.09 (-7.7-3) NK 
FEV1 (% predicted) NK 80 (37-110); (N=12)b 82.2 (68-145); (N=12)b 
FVC (% predicted) NK 88.5 (51-106); (N=12)b 88.45 (73-161); (N=12)b 
Lavage culture verified infection (N) 0 10c NK 
Lavage neutrophils (106/ml) 0.007 (0-0.0157) 0.54 (0.03-4); (N=18)d NK 
Lavage mononuclear cells (106/ml) 0.096 (0-0047-0.38) 0.4 (0.04-2.5); (N=18)d NK 
Lavage elastase positive:negative (N) 0:9 14:11 11:8 
Lavage free elastase activity (nM)e 0 74 (8-1250)  40 (2-1657) 
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3.1. SP-D expression in CF airway lavage fluid is inversely related to infection, markers of 
neutrophilic inflammation and age:  SP-D was detected by ELISA in CF lavage fluid from 
cohort A (5332ng/ml; 1957-9595) at levels 2.4 fold higher than control BALF (2214ng/ml; 
1545-2902) (figure 1a).  Within CF cohort A SP-D expression was 3.6 fold lower in those with 
clinically important infections (1892ng/ml; 359-6376) compared to those without (6879ng/ml; 
4683-12200) (figure 1b).  SP-D expression negatively correlated with elastase activity (data not 
shown: Spearman r=-0.71; p=0.004) and CXCL8 expression (data not shown: Spearman r=-0.45; 
p=0.02) in CF cohort A.  SP-D expression also negatively correlated with age in CF cohort A 
(figure 2a: Spearman r=-0.4; p=0.04).  Patients in whom elastase activity was detected were 
significantly older than elastase negative counterparts (9.2 years; 3.6-13.2 vs. 2 years; 0.7-6.4: 
p=0.02) and infected patients were also substantially older than their non-infected counterparts 
(8.7 years; 3.6-13.5 vs. 2.8 years; 0.4-8.8) although this did not reach statistical significance 
(p=0.08).   Data for microbiology or CXCL8 expression were not available for cohort B (median 
BALF SP-D: 1073ng/ml; 239-2414), however we confirmed that SP-D expression correlated 
negatively both with elastase activity (data not shown: Spearman r=-0.8; p=0.002) and age (data 
not shown: Spearman r=-0.47; p=0.04).   
 
3.2. Measuring SP-D lectin activity with a functional assay:  SP-D lectin activity was 
measured in a zymosan binding assay.  Native SP-D interactions with zymosan were maltose 
and EDTA sensitive (figure 3a) as previously described [15].  When tested in the same assay, 
lavage fluid from CF cohorts A and B as well as the control cohort contained substantial 
amounts of SP-D which failed to bind zymosan.  Within control and CF lavage, a minor band 
migrating 3-4kDa and occasionally 6-8kDa (figure 3b&c; closed arrows) higher than the main 
SP-D monomer (figure 3b&c; asterix) were sometimes identified by Western blot as part of the 
non-binding SP-D pool.  Similar minor forms of higher molecular weight SP-D have previously 
been described [7, 18].  Occasionally, a minor band migrating below the main SP-D monomer 
was observed in CF lavage which contained active neutrophil elastase (figure 3b; open arrow).  
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This likely corresponds to partially proteolysed SP-D as previously described in CF [6, 7].  
Lavage SP-D interactions with zymosan were also predominantly calcium and maltose 
dependent (Figure 3c).  As reported in previous studies [9-11], calcium chelation with EDTA in 
CF lavage sometimes resulted in a loss of detectable SP-D due to proteolysis (data not shown).  
Protease inhibition with 1mM PMSF preserved SP-D under these conditions (figure 3c; right 
hand panel).  The pH of airway secretions in normal and pathological conditions has been 
reported to be slightly acidic.  The pH dependence of SP-D zymosan interactions were therefore 
also tested and were found to be stable when tested between pH 5.6 and 7.6 (figure 3d).   
When maltose-agarose was used as a substrate for lavage fluid SP-D binding, the pattern of 
binding was largely similar to that obtained with zymosan (figure 4).  However in some cases 
(figure 4; samples 2b & 3b) SP-D demonstrated weaker binding activity towards maltose-
agarose. 
 
3.3. Restricted lavage SP-D lectin activity is related to infection and markers of 
neutrophil inflammation:    Following a zymosan binding assay and western blot of bound and 
non-bound fractions, the percentage of zymosan bound SP-D was quantified by densitometry 
for all available patient samples.  In CF cohort A, 3/25 samples with the lowest SP-D 
concentration contained insufficient antigen to be quantified in the zymosan binding assay and 
are not included in subsequent analyses.  In cohort B, 6/19 BALF samples were similarly below 
the limit of detection for the assay.  Those samples below the limit of detection for western blot 
were also observed to have SP-D <500ng/ml by ELISA.  Further concentration of these samples 
was not undertaken as this has been reported to alter the molecular structure of SP-D in a 
functionally relevant manner [19].  A substantial proportion of SP-D in lavage from CF cohort A 
failed to bind zymosan (55%) and similar findings were observed in the control cohort (46%) 
however there was no difference between the groups, (p=0.56), (figure 5a).  Similar findings 
were observed in CF cohort B where 61% of SP-D failed to bind zymosan (data not shown).  The 
proportion of SP-D with zymosan binding activity was significantly lower in infected compared 
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to non-infected CF patients (p=0.02; figure 5b).  The majority of native purified SP-D included as 
a positive control in all assays for cohorts A and B exhibited binding to zymosan (95%; 90-98).     
Total zymosan binding SP-D (calculated using ELISA and zymosan binding assay data) was 
higher in CF cohort A than controls (p=0.01; figure 6a) but was significantly lower in CF samples 
with culture confirmed infection compared to those without (p=0.04; figure 6b).   
Samples containing the lowest detectable SP-D zymosan binding activity were tested for the 
ability to inhibit exogenously added native SP-D binding to zymosan.  Substantial inhibition of 
native SP-D binding to zymosan was not observed by lavage samples yielding a positive culture 
for Aspergillus fumigatus (figure 7), Burkholderia cepacia or Stenotrophomonas maltophilia (data 
not shown) suggesting that competitive inhibition by microbial ligands within these samples 
was not responsible for the restricted lectin activity.  Furthermore, addition of the serine 
protease inhibitor PMSF had little impact on the assay results in the presence of calcium (figure 
7).   
In samples where active elastase was present, the majority of SP-D in the non-bound fraction 
was of identical molecular weight to the bound material and SP-D degradation products were 
only occasionally observed in a small minority of samples by western blot (figure 3b).    Despite 
this, both the percentage and total concentration of SP-D with lectin activity was significantly 
lower in elastase positive samples from cohort A compared to those in which elastase was not 
detected (figure 8a & b).  The percentage and total concentration of SP-D binding to zymosan 
also negatively correlated with expression of the neutrophilic chemokine, CXCL8, in this cohort, 
(figure 8c & d).  Similar relationships between elastase activity and SP-D lectin activity were not 
observed in cohort B (data not shown), however those analyses may have been compromised by 
the smaller sample size and the fact that almost half of the elastase positive samples in that 
cohort were not detectable in the zymosan binding assay and are not therefore represented in 
the analysis.  Furthermore, CXCL8 expression data was not available in cohort B. 
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3.4. Oligomeric variants of SP-D in CF airway lavage fluid exhibit distinct lectin activity:  
As the oligomeric status of SP-D is known to have a profound impact on its ligand binding 
activity [20-22], native gel electrophoresis was used to assess the oligomeric status of SP-D in 
lavage fluid.  A range of oligomeric forms were evident in both control and CF samples (Figure 
9a) including very large oligomers barely capable of entering the gel.  Analysis of bound and 
non-bound fractions from a zymosan binding assay, revealed that high oligomeric forms of SP-D 
predominantly migrated with zymosan whilst low oligomeric forms remained in the 
supernatant (Figure 9b; upper panel).    Intermediate oligomeric forms evident in the non-
fractionated blot (arrow; figure 9a), were less prevalent following the binding assay.  Partial 
assembly of SP-D trimers to multimers in response to ligand binding has previously been 
reported [19] and we suggest that these intermediate forms may have formed larger oligomers 
in response to zymosan binding.  
The size distribution of SP-D was also examined by gel chromatography of lung lavage fluid 
from six CF patients.  Two distinct populations of SP-D separating at different molecular weights 
were observed in all samples tested (Figure 10a).  Although present in different proportions, 
both populations eluted at the same position in all lavage samples.  The mobility of both 
populations relative to globular standards was consistent with ‘high’ (dodecameric and 
multimeric) and ‘low’ (trimeric) forms of SP-D previously described by Leth-Larsen [22].  
Fractions from five of these samples were available for parallel assays of lectin activity.  This 
showed substantial calcium dependent SP-D mannan binding activity in fractions corresponding 
to high oligomeric forms whilst SP-D in fractions of lower oligomeric form exhibited only weak 
or absent mannan binding activity in any of the samples tested (figure 10b & c). 
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4. DISCUSSSION: 
We present a comprehensive analysis of SP-D expression and function in lung secretions from 
paediatric CF patients and controls.  To our knowledge, this is the first systematic analysis of SP-
D lectin activity in the CF population.   
In keeping with previous studies, SP-D expression was reduced in lavage fluid from CF patients 
with infection or evidence of inflammation compared to non-infected CF patients.  Importantly 
however, SP-D was present in all but a few CF samples representing both bronchial (Cohort A) 
and bronchoalveolar (Cohort B) airway when tested by specific dual monoclonal antibody 
ELISA.  There has been considerable variability in reported values for BALF SP-D in CF, ranging 
from a near absence [4, 23] to expression in the µg/ml range [5].  Several factors may explain 
this variability:  In addition to differences in BAL sampling and processing methodology, 
techniques used to measure SP-D in CF range from semi-quantitative western blot [6, 7] to 
ELISA, some of which use antibodies reactive with human SP-D but raised against a different 
species [5, 23].  Also, some previous studies applied specific microbial density thresholds to 
define infection [5, 6], whereas we define infection on the basis of reported positive culture in 
line with other reports [12, 24-26].  This may explain why we observe immunoreactive SP-D 
both by Western blot and ELISA even in culture positive CF samples.  Also, in some previous 
studies, the proportion of patients with culture verified infection was higher [4, 7] and the age 
range of CF patients substantially older [7, 23] than those studied by us.  This may be relevant in 
light of the negative correlation between age, infection and SP-D concentration reported here.  
Previous population based studies have described increased circulating SP-D with age [27].  The 
age related decline in lung rather than circulating SP-D observed here probably reflects 
advancing lung disease in this population, an interpretation supported by the increased 
prevalence of infection and active elastase in older patients.   In summary, our observation of 
substantial SP-D expression in CF confirms some reports [5, 7] but not others [4].  However the 
observed negative association between SP-D, infection and inflammation agrees with the 
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findings of a number of previous studies [4-6] and suggests that detectable SP-D is subject to 
dynamic modulation in the face of ongoing inflammatory disease.   
The primary objective of this study was to examine the carbohydrate binding activity of SP-D in 
CF patients.  We observed considerable heterogeneity in the capacity of both CF and control 
lavage SP-D to bind the yeast derived mannan rich particle, zymosan.  Such heterogeneity was 
observed in lavage fluid collected from two distinct cohorts of CF patients.  Lavage collected 
from cohort A was mainly of bronchial origin whilst that from cohort B was reflective of 
bronchoalveolar lavage according to the lavage procedure used.  Nevertheless, inflammatory 
activity (reflected in free elastase activity) was relatively similar between both cohorts which 
may reflect the largely bronchial nature of airway disease in CF.  Although SP-D inactivation by 
CF relevant proteases is well described, the functional consequences of this remain unclear as 
physiological concentrations of calcium render SP-D resistant to proteolysis [6, 9, 11]. As 
previously reported, SP-D expression was lower in elastase positive CF samples here, however 
in the majority of cases substrate bound and non-bound SP-D migrated at an identical molecular 
weight on SDS-PAGE under reducing conditions.  The absence of a major population of 
proteolytically fragmented SP-D in this study is consistent with two previous reports [7, 12] and 
indicates that limited proteolysis is not responsible for the observed restriction of lectin 
activity.  Minor forms of SP-D migrating 3-8kDa higher than the main monomer were observed 
in many samples but did not associate with zymosan or maltose-agarose and were exclusively 
found in the supernatant fraction.  These resemble forms of SP-D previously observed in CF 
BALF [7] and are thought to represent a hyper-glycosylated form of SP-D speculated by Mason 
et al. to limit oligomerisation to trimeric species [18].  The inability of these forms to bind 
saccharide ligands in our assays is consistent with the well documented reduction of opsonic 
and anti-viral activity of low oligomeric forms of SP-D [20-22].  In light of this, we used both 
native gel electrophoresis and size exclusion chromatography to further investigate the 
molecular distribution and lectin activity of SP-D in airway lavage.  SP-D capable of binding 
zymosan exhibited features of high molecular weight when assessed by western blot under 
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native conditions, whilst non-bound material was of lower molecular weight.  This observation 
was confirmed by size exclusion chromatography which revealed two populations of SP-D in CF 
airway lavage fluid.  Consistent with data from the zymosan binding assay, high molecular 
weight SP-D bound to yeast derived mannan in a calcium dependent fashion whilst lower 
molecular weight material exhibited limited if any capacity to recognise such polysaccharides.  
The distribution of these two populations of SP-D is consistent with reports of a common SP-D 
polymorphism influencing the structure and lectin activity of SP-D.   The presence of Thr at 
position 11 limits SP-D oligomerisation to trimers with restricted lectin activity whilst Met at 
that position gives rise to dodecameric oligomers with unrestricted lectin activity towards 
complex carbohydrates and a range of bacteria and Influenza virus in addition to functionally 
restricted trimeric oligomers [22].  Although the frequency of that polymorphism was not 
determined here, its distribution among Danish CF patients is not significantly different from 
the normal population [28].  In addition to these common polymorphisms, post-translational 
modification by nitric oxide derivatives [29] and elements of the neutrophil respiratory burst 
[30, 31] also contribute to plasticity of SP-D structure and function.  Reactive oxygen-nitrogen 
intermediates of the innate inflammatory response were not reported to have any appreciable 
impact on SP-D lectin activity when tested using similar pulldown methodology as that 
employed here; rather, these intermediates diminished the agglutinating activity of SP-D [30, 
31].  Importantly, agglutination is not a critical determinant of zymosan mobility under the 
assay conditions used here.  Taken together, this suggests that the functional heterogeneity 
reported here is not primarily due to post-translational modifications by reactive oxygen-
nitrogen intermediates.  However, a thorough assessment of the presence of such post-
translational modifications in clinical BAL samples will be required to fully understand the 
impact of these processes on SP-D activity in vivo.     
Lower zymosan binding activity was observed among SP-D from CF patients with clinically 
important infections.    Although the number of patients with infections was limited owing to the 
lower rates of chronic infection in the pediatric CF population, the data nevertheless 
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demonstrate significant differences in the expression and lectin activity of SP-D in the face of 
infection. One interpretation of this finding, and that of reduced SP-D expression in infected 
patients, is that sequestration by adherence to bacteria and subsequent clearance during lavage 
processing explains the observed deficit.  Although paired cellular and acellular samples were 
not available to address this possibility, a previous study of CF and non-CF patients with and 
without infection, indicates that poorly regulated inflammation rather than infection per se, is 
responsible for SP-D depletion during infectious disease [5].  That study also reported no 
difference in SP-D content between sonicated, cellular BALF and cleared acellular BALF, nor did 
EDTA treatment of BALF prior to clearance (to dissociate any potential SP-D complexes) have 
any effect on SP-D content.  Our own unpublished data confirm the enhanced anti-viral 
properties of size excluded high oligomeric form alveolar proteinosis SP-D towards Influenza-A 
virus.  Intriguingly, these highly oligomerised forms of SP-D also agglutinate Escherichia coli into 
very large aggregates (up to 50µm and occasionally 80 µm diameter; data not shown) and may 
play an important role in facilitating effective mucociliary clearance of bacteria from the lower 
airway; a process likely to be of critical importance in the CF airway.  It is possible that 
enhanced mucociliary clearance of large aggregates may partially explain the depressed SP-D 
expression in the airway of CF patients with infection observed here and elsewhere.  This would 
be predicted to lead to the preferential clearance of higher order oligomers of SP-D from the 
lower airway, which may also explain the relatively restricted lectin activity of SP-D in CF 
patients with infection, where lower order oligomers would dominate.  Nevertheless, even 
among non-infected and control patients, considerable heterogeneity of SP-D lectin activity was 
observed.  We have recently described functionally relevant heterogeneity of SP-D oligomeric 
form in preterm neonatal BALF using methodology similar to that described here [15].  
Oligomeric diversity has also been observed in SP-D from asthmatic and chronic obstructive 
pulmonary disease patients [32, 33] but was not examined functionally.  Few other systematic 
reports of SP-D activity in clinical populations have been published.  One study reported 
maltose dependent agglutinating activity of BALF from tracheostomy patients towards 
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Pseudomonas aeruginosa as a surrogate measure of SP-D agglutinating activity [34].  
Interestingly, although the agglutinating activity of lavage correlated with SP-D content, this 
was found to be a relatively weak association indicating either that other maltose inhibitable 
factors were contributing to the activity, or that not all SP-D detected by ELISA participated in 
the agglutinating activity.  In light of data reported here and previously [15] we argue that it is 
important to rely not only on quantitative assays of SP-D content when considering the status of 
SP-D in a clinical population but also to consider what proportion of the recovered material is 
functionally active in any given assay.  It is also important to consider what aspect of SP-D 
activity one wishes to measure.  Both lectin and agglutinating activity are profoundly influenced 
by the oligomeric state of SP-D however how this influences the reported anti-inflammatory 
activity of SP-D is not well understood.  Understanding this relationship will be an important 
step in fully understanding the influence of SP-D oligomeric diversity upon the range of 
reported SP-D activities 
The importance of SP-D oligomeric state in controlling infection in vivo is also not well 
understood.  Heritable variation in SP-D oligomerisation has been implicated in clinically 
relevant responses to respiratory syncitial virus [35, 36] and Mycobacterium tuberculosis [37].  
In the case of MBL (another collectin subject to functionally relevant oligomeric variation), 
amino acid changes influencing multimerisation and carbohydrate binding activity act in 
combination with promoter polymorphisms to confer a state of functional and quantitative MBL 
insufficiency [38] associated with earlier and more severe lung pathology in CF [39].  Increased 
oligomeric complexity in SP-A has also been recently associated with better lung function in CF 
[40].  The only study published to date in CF identified no association between SP-D Met/Thr 
genotype and disease progression [28], however larger studies looking at the full range of 
factors influencing SP-D structure/function will probably be required to reach a firm conclusion.  
In summary, our data show that SP-D is found in substantial quantities in the paediatric CF lung 
but exists as a functionally and structurally heterogeneous population in both this and the 
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control population.  As our surgical control population did not have symptoms of airway disease 
at the time of sampling it will be interesting to examine SP-D expression and lectin activity in 
non-CF patients with suppurative lung disease to examine whether the link between infection, 
inflammation and SP-D activity observed here is a specific feature of CF.   We propose that 
structural heterogeneity may be as important (if not more so) than proteolytic digestion in 
determining the functionality of SP-D in CF.  Although factors influencing SP-D oligomerisation 
have been identified, how this may differ in health and disease and the contribution this makes 
to clinical outcome requires further investigation. 
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6. FIGURE LEGENDS 
Figure 1) SP-D expression in CF and control lavage fluid:  A) SP-D was measured in CF 
cohort A (n=25) and controls (n=9) by sandwich ELISA.  B) The CF cohort was divided into 
those samples in which clinically relevant microorganisms were recovered (infection status 
positive; n=10) and those which either yielded no microbiological culture or yielded 
microorganisms regarded either as part of the normal microflora or not clinically significant 
(infection status negative; n=15) as detailed in the materials and methods.  Abbreviated 
microorganisms are as follows: P. aer. = Pseudomonas aeruginosa, H. Infl. = Haemophilus 
influenzae, B. cep. = Burkholderia cepacia, S. malto. = Stenotrophomonas maltophilia, A. fum. = 
Aspergillus fumigatus, M. cat. = Moraxella catarrhalis.  Bars refer to medians. 
 
Figure 2) SP-D expression negatively correlates with age in CF:  Lavage SP-D concentration 
was plotted against patient age in CF cohort A (n=25).  The r- and p-values refer to Spearman’s 
rank correlation.  As stated in the text, a similarly significant correlation between age and SP-D 
concentration was also observed in CF cohort B (data not shown; Spearman r=-0.47; p=0.04).  
 
Figure 3) Assessing SP-D functional activity in CF and control lavage fluid:  A) Native 
purified SP-D was incubated with a washed zymosan pellet in the presence of 10mM CaCl2, 
10mM EDTA or 10mM CaCl2 with 100mM D-maltose.  Following a 30 minute incubation with 
occasional agitation, zymosan was pelleted by centrifugation at 10,000g/1 minute.  
Supernatants were carefully aspirated to fresh tubes.  The pellet was washed in the appropriate 
buffer and treated with 20mM EDTA.  Both pellet (P) and supernatant (S) fractions were boiled 
for 2 minutes in SDS sample buffer with β-mercaptoethanol prior to separation by SDS-PAGE on 
10% gels followed by Western blot for SP-D.  SP-D mobilises with the zymosan pellet in the 
presence of calcium but not in the presence of maltose or EDTA.  Data are representative of 
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three or more independent experiments.  B)  Control and CF lavage as well as positive control 
native purified SP-D were similarly assayed for their capacity to bind to zymosan in the 
presence of 10mM CaCl2.  The majority of native SP-D mobilised with the zymosan pellet.  In the 
case of both control and CF, the major SP-D band migrated with an identical molecular weight as 
native purified SP-D (*).  A significant proportion of SP-D in both control and CF lavage failed to 
bind to zymosan and was found in the supernatant fraction.  In addition to the main SP-D 
monomer additional bands migrating 3-4 and 6-8kDa higher than the main SP-D monomer were 
observed in some samples under reducing conditions (closed arrows) but only in the non-
bound supernatant fraction.  A minor lower molecular weight band, probably corresponding to 
a proteolytic fragment of SP-D, was observed in a small number of samples (open arrow).  Data 
are representative of at least 12 independent experiments.  C)  CF lavage was incubated with a 
washed zymosan pellet in the presence of 10mM CaCl2, 10mM EDTA or 10mM CaCl2 with 
100mM D-maltose as described in panel A.  Following separation of pellet and supernatant 
fractions by SDS-PAGE under reducing conditions, the majority of SP-D was seen to migrate 
with zymosan in a maltose and EDTA inhibitable fashion.  Symbols refer to bands described in 
panel B.  Data are representative of at least 3 (maltose) and 2 (EDTA + PMSF) independent 
experiments. D) Zymosan binding assays were undertaken for three CF lavage fluid samples at 
pH 5.6, 6.6 and 7.6.  No substantial differences in the proportion of bound and non-bound SP-D 
were observed between assays carried out at different pH. 
 
Figure 4)  Assessing lavage SP-D binding activity towards zymosan and maltose agarose:  
CF lavage was incubated either with maltose agarose (A) or zymosan (B) for 30 minutes in the 
presence of 10mM CaCl2.  Native purified SP-D was included as a positive control.  Following 
centrifugation, the supernatant (S) fraction was carefully aspirated.  The pellet (P) fraction was 
washed and resuspended in 20mM EDTA.  Both fractions were separated by SDS-PAGE under 
reducing conditions and blotted for SP-D.  In addition to the main SP-D monomer, a minor 
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population of SP-D migrating 3-8kDa above this was evident in the non-bound supernatant.  
Additional bands migrating at approximately 95kDa are thought to represent partially non-
reduced SP-D dimers.  Data are representative of 3 independent experiments addressing 10 
distinct lavage fluid samples.  
 
Figure 5)  SP-D zymosan binding activity in CF and control lavage:  A) All available lavage 
samples were subjected to a zymosan binding assay and following SDS-PAGE of pellet and 
supernatant fractions, blots were probed for SP-D.  The percentage of SP-D associated with the 
zymosan pellet was quantified by analysis of pellet and supernatant bands using ImageJ 
software.  Data are presented for control (n=9) and CF cohort A (n=22; 3 CF samples had too 
little SP-D to be quantified by the zymosan binding assay).   B) CF samples were separated into 
those with clinically important infections (infection status positive: n=7; 3 CF samples had too 
little SP-D to be quantified by the zymosan binding assay) or not (infection status negative: 
n=15) as described in the materials and methods. The identities of the infectious 
microorganisms are detailed in abbreviated form as detailed in the legend to figure 1b.  Bars 
refer to medians. 
 
Figure 6)  SP-D binding activity in CF and control lavage:  Data from the zymosan binding 
assay was combined with that from the ELISA to calculate the amount of lavage SP-D with 
zymosan binding activity.  A) Data are presented for control (n=9) and CF cohort A (n=22; 3 CF 
samples had too little SP-D to be quantified by the zymosan binding assay).  B) CF samples were 
separated into those with clinically important infections (infection status positive: n=7; 3 CF 
samples had too little SP-D to be quantified by the zymosan binding assay) or not (infection 
status negative: n=15) as described in the materials and methods. The identities of the 
infectious microorganisms are detailed in abbreviated form as detailed in the legend to figure 
1b.  Bars refer to medians. 
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Figure 7) Culture positive CF lavage with minimal endogenous functional SP-D does not 
substantially inhibit exogenous native SP-D binding activity towards zymosan:  CF lavage 
which yielded positive microbiological culture and was found to contain SP-D with weak 
capacity to interact with zymosan was tested for its ability to inhibit exogenously added native 
SP-D binding to zymosan.  Experiments were carried out in the presence or absence of 1mM 
PMSF to inhibit serine protease activity present in these samples.  Lavage fluid was 
reconstituted with (+NhSP-D) or without (-NhSP-D) purified native SP-D.  Positive controls in 
the absence of lavage were also included (lanes 1-4).  Samples were incubated with zymosan in 
the presence of 10mM CaCl2.  Following centrifugation, pellet and supernatant fractions were 
separated by SDS-PAGE under reducing conditions and blotted for SP-D.  The majority of 
exogenously added SP-D bound to zymosan in these experiments and PMSF had little impact on 
binding activity in the presence of 10mM CaCl2.  Data are representative of 3 independent 
experiments. 
 
Figure 8)  The percentage and amount of functional SP-D in CF lavage is inversely related 
to neutrophil elastase activity and CXCL8 expression: CF lavage samples with sufficient SP-D 
to enable analysis in the zymosan binding assay were separated into those samples with 
detectable elastase activity (elastase status positive; n=11) or not (elastase status negative; 
n=11) in order to assess differences in the percentage (A) and amount (B) of SP-D capable of 
binding to zymosan between these two groups.  Bars refer to medians, p-values refer to the 
Mann Whitney test.  The percentage (C) and amount (D) of SP-D capable of binding to zymosan 
was also plotted against CXCL8 concentration for each sample (n=22 in both cases).  R- and p-
values refer to Spearman’s correlation.  
 
Figure 9)  Lavage SP-D with zymosan binding activity exhibits features of higher 
olgomeric form:  A) CF and control lavage fluid was separated on 3-8% Tris-acetate 
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polyacrylamide gels under native conditions.  Following transfer to nitrocellulose, blots were 
probed for SP-D.  B)  CF and control lavage as well as positive control native purified SP-D were 
subjected to a zymosan binding assay in the presence of 10mM CaCl2.  Zymosan bound (pellet;P) 
and non-bound (supernatant;S) fractions were isolated and prepared for either native PAGE 
(top panel) or SDS-PAGE under reducing conditions (bottom panel).  Under native conditions 
the majority of zymosan bound material in the pellet fraction exhibited features of high 
oligomeric form and was unable to significantly migrate into the gel.  By contrast, non-bound 
material from the supernatant migrated with characteristics of lower oligomeric form.  The 
arrow in panel A highlights an intermediate oligomeric form of SP-D observed in unfractionated 
lavage  which was less prevalent following the zymosan binding assay.    
Figure 10)  Two populations of SP-D of different oligomeric form and exhibiting distinct 
lectin activity are present in CF airway fluid:  A) Six CF lavage fluid samples were subjected 
to Superose 6 gel filtration and fractions were assessed for SP-D content by ELISA.  Two distinct 
peaks of different molecular weight were observed in all samples tested.  The elution profile of 
three standards - blue dextran (BD), thyroglobulin (TG) and alcohol dehydrogenase (ADH) - and 
their molecular weights are indicated at the top of the panel.  B)  For five of the samples 
separated by gel filtration, individual fractions were also assessed for calcium dependent SP-D 
binding to mannan in a solid phase assay.  Larger molecular weight SP-D oligomers exhibited 
preferential binding to mannan but little or no binding was observed from the lower molecular 
weight fractions.  C) The inclusion of EDTA in mannan binding assays was sufficient to inhibit all 
SP-D/mannan interactions. 
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FUNCTIONAL HETEROGENEITY OF PULMONARY SURFACTANT PROTEIN-D IN CYSTIC FIBROSIS . 
Highlights 
1. SP-D is abundantly expressed in CF lung fluid 
2. SP-D in CF lung fluid is structurally and functionally heterogenous 
3. SP-D expression and function correlates negatively with infection and inflammation 
4. Oligomeric form is a major determinant of SP-D function in CF and control patients 
